336 related articles for article (PubMed ID: 10944743)
1. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
2. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
Clegg A; Bryant J
Expert Opin Pharmacother; 2001 Apr; 2(4):623-39. PubMed ID: 11336612
[TBL] [Abstract][Full Text] [Related]
3. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
4. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
5. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
6. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
7. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
[No Abstract] [Full Text] [Related]
8. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
9. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
Rieckmann P; Toyka KV
Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
[TBL] [Abstract][Full Text] [Related]
10. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
11. Immunologic therapy for secondary and primary progressive multiple sclerosis.
Myers LW
Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
[TBL] [Abstract][Full Text] [Related]
12. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
Napier JC; Francis R; Wright G
BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
[No Abstract] [Full Text] [Related]
13. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
Pender MP; Wolfe NP
Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
[TBL] [Abstract][Full Text] [Related]
14. Confusion over UK beta-interferon "trials".
Dean M
Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
[No Abstract] [Full Text] [Related]
15. No cash to implement NICE, health authorities tell MPs. The National Institute for Clinical Excellence.
Burke K
BMJ; 2002 Feb; 324(7332):258. PubMed ID: 11936127
[No Abstract] [Full Text] [Related]
16. Multiple sclerosis treatment 2001.
Rolak LA
Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
[TBL] [Abstract][Full Text] [Related]
17. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
18. [Immunosuppressive medication in multiple sclerosis].
García Merino JA
Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
[TBL] [Abstract][Full Text] [Related]
19. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
Confavreux C; Vukusic S
Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
Garattini L; Ghislandi F; Da Costa MR
Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
